461 related articles for article (PubMed ID: 21640121)
1. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
3. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
Fang Y; Debunne M; Vercauteren M; Brakenhielm E; Richard V; Lallemand F; Henry JP; Mulder P; Thuillez C
J Cardiovasc Pharmacol; 2012 Mar; 59(3):260-7. PubMed ID: 22075752
[TBL] [Abstract][Full Text] [Related]
4. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
6. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Toblli JE; Cao G; Giani JF; Muñoz MC; Angerosa M; Dominici FP
J Hypertens; 2011 Aug; 29(8):1613-23. PubMed ID: 21720265
[TBL] [Abstract][Full Text] [Related]
8. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.
Conraads VM; Metra M; Kamp O; De Keulenaer GW; Pieske B; Zamorano J; Vardas PE; Böhm M; Dei Cas L
Eur J Heart Fail; 2012 Feb; 14(2):219-25. PubMed ID: 22147202
[TBL] [Abstract][Full Text] [Related]
9. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
11. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X.
Sen N; Tavil Y; Erdamar H; Yazici HU; Cakir E; Akgül EO; Bilgi C; Erbil MK; Poyraz F; Okyay K; Turfan M; Cemri M
Anadolu Kardiyol Derg; 2009 Oct; 9(5):371-9. PubMed ID: 19819787
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Merabet N; Bellien J; Glevarec E; Nicol L; Lucas D; Remy-Jouet I; Bounoure F; Dreano Y; Wecker D; Thuillez C; Mulder P
J Mol Cell Cardiol; 2012 Mar; 52(3):660-6. PubMed ID: 22155238
[TBL] [Abstract][Full Text] [Related]
14. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Kobayashi M; Machida N; Mitsuishi M; Yamane Y
Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
Gao Y; Vanhoutte PM
J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice.
Baumhäkel M; Schlimmer N; Büyükafsar K; Arikan O; Böhm M
J Pharmacol Exp Ther; 2008 Jun; 325(3):818-23. PubMed ID: 18364472
[TBL] [Abstract][Full Text] [Related]
17. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
Wolf SC; Buck-Müller N; Görner S; Risler T; Brehm BR
Med Klin (Munich); 2003 Jan; 98(1):1-6. PubMed ID: 12540987
[TBL] [Abstract][Full Text] [Related]
18. Selective Heart Rate Reduction Improves Metabolic Syndrome-related Left Ventricular Diastolic Dysfunction.
Merabet N; Fang Y; Nicol L; Monteil C; Rémy-Jouet I; Henry JP; Wecker D; Le Bouter-Banon S; Roussel J; Richard V; Thuillez C; Mulder P
J Cardiovasc Pharmacol; 2015 Oct; 66(4):399-408. PubMed ID: 26222991
[TBL] [Abstract][Full Text] [Related]
19. Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage.
Ozakca I; Arioglu-Inan E; Esfahani H; Altan VM; Balligand JL; Kayki-Mutlu G; Ozcelikay AT
Am J Physiol Heart Circ Physiol; 2013 May; 304(9):H1267-76. PubMed ID: 23457011
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
